Centhaquin - Pharmazz

Drug Profile

Centhaquin - Pharmazz

Alternative Names: PMZ 2010

Latest Information Update: 10 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Midwestern University; Pharmazz
  • Developer Pharmazz
  • Class Antihypertensives; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemorrhagic shock
  • Phase I Postoperative pain

Most Recent Events

  • 03 Feb 2017 Phase-II clinical trials in Haemorrhagic shock in India (IV)
  • 31 Jan 2017 Pharmazz receives notice of issuance for Centhaquin for Resuscitation (hypotensive) in Japan
  • 12 Nov 2016 Pharmacokinetics data from a phase I trial in Haemorrhagic shock (In volunteers) presented at the 89th Annual Scientific Sessions of the American Heart Association (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top